Indeed, it was shown that primary CD34+ CML cells depend on upregulated metabolism for their survival as demonstrated by stable isotope-assisted metabolomics and functional assays, and that the combination of Imatinib with the antibiotic tigecycline, that inhibits mitochondrial protein translation, selectively eliminates CML-LSCs [43]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.